secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-08-05T20:04:48+00:00
Accession:  0001628280-26-053308
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Q2 2026 net loss $62.5M ($1.04/share); Fanapt sales up 23% to $36M; reiterates FY revenue guidance $240-290M
--------------------------------------------------------------------------------

- Net loss $62.5M ($1.04 diluted EPS) in Q2 2026 vs net loss $27.2M ($0.46) in Q2 2025; operating loss $62.4M.
- Fanapt net product sales $36.0M (+23% YoY); total prescriptions up 31% YoY.
- Total net product sales $50.5M (-4% YoY); HETLIOZ sales $5.6M (-66% YoY) due to $7M shipment shift to Q3.
- Cash $170.0M as of June 30, 2026, down $32.3M in Q2; expects to fund operations through end of 2027.
- FY 2026 total revenue guidance reiterated at $240-290M; BYSANTI launch H2 2026; Quimilza PDUFA Dec 12, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/0001628280-26-053308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer